Roth Capital starts Natera coverage with a USD 475 target for Natera stock

Published on 10/26/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roth Capital set a USD 475 target on October 23, 2026. Natera stock costs EUR 361.80 on October 26, 2026, and revenue hit USD 752.75 million.

Growth and analyst signals

Roth Capital initiated coverage with a USD 475 target on October 23, 2026.
Natera reported USD 752.75 million in second-quarter revenue on August 6, 2026.
Natera stock trades at EUR 361.80 at 11:17 a.m. CET at Lang & Schwarz on October 26, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera, Inc. (ISIN US6323071042) was trading at EUR 361.80 at Lang & Schwarz on October 26, 2026, at 11:17 a.m. CET. Roth Capital initiated coverage of Natera with a Buy rating and a USD 475 price target on October 23, 2026, according to Marketscreener.

Roth sees oncology growth

Roth Capital's target is anchored in Natera's oncology diagnostics business, including minimal residual disease testing. The analyst note described the company as a growth leader in diagnostics and pointed to continued estimate-revision potential, as reported on October 23, 2026 by Marketscreener.

The target sits above the latest U.S. closing quote cited in the analyst coverage, but the euro reference price and that U.S. value belong to different venues and currencies. The comparison is therefore kept separate from the Lang & Schwarz quotation.

What does the revenue figure mean?

Natera's second-quarter revenue reached USD 752.75 million, up 37.70 percent from the year-earlier period and above the USD 661.24 million consensus estimate, according to MarketBeat in its October 19, 2026 report. Adjusted earnings per share showed a loss of USD 0.47, narrower than the USD 0.49 consensus loss. The figures came from the quarter reported on August 6, 2026.

Three dated Natera developments

On August 6, 2026, Natera reported second-quarter revenue of USD 752.75 million and adjusted earnings per share of minus USD 0.47, according to MarketBeat. On October 19, 2026, Canaccord Genuity raised its target from USD 375.00 to USD 500.00 and kept a Buy rating, as reported by MarketBeat. On October 23, 2026, Roth Capital initiated coverage with a USD 475.00 target, according to Marketscreener.

Dates for the next report

Natera's next quarterly results are scheduled for November 11, 2026, after the market close, according to Fintel. The date gives investors the next formal checkpoint for revenue growth, test volume and profitability.

Stock price and reporting checkpoint

Natera's U.S. listing is on Nasdaq, where the stock was last quoted at USD 403.95 on October 23, 2026, according to a market data page. The quoted 52-week range was USD 181.00 to USD 437.41, while market capitalization stood at USD 58.2 billion on that date.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.